REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 152 filers reported holding REATA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 3.61 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $7,800,069 | +56.2% | 205,319 | +3.3% | 0.00% | +100.0% |
| Q3 2022 | $4,994,085 | -17.3% | 198,730 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $6,039,405 | -1.9% | 198,730 | +5.8% | 0.00% | +100.0% |
| Q1 2022 | $6,155,014 | +6.7% | 187,882 | -14.1% | 0.00% | 0.0% |
| Q4 2021 | $5,768,000 | -73.8% | 218,725 | 0.0% | 0.00% | -80.0% |
| Q3 2021 | $22,006,000 | -27.2% | 218,725 | +2.4% | 0.01% | -28.6% |
| Q2 2021 | $30,216,000 | +56.4% | 213,497 | +10.2% | 0.01% | +75.0% |
| Q1 2021 | $19,316,000 | -22.2% | 193,738 | -3.5% | 0.00% | -33.3% |
| Q4 2020 | $24,820,000 | +21.3% | 200,774 | -4.4% | 0.01% | +20.0% |
| Q3 2020 | $20,463,000 | -44.9% | 210,053 | -11.7% | 0.01% | -54.5% |
| Q2 2020 | $37,119,000 | +3.1% | 237,912 | -4.6% | 0.01% | -15.4% |
| Q1 2020 | $36,009,000 | -31.0% | 249,476 | -2.3% | 0.01% | -13.3% |
| Q4 2019 | $52,194,000 | +446.6% | 255,315 | +114.7% | 0.02% | +400.0% |
| Q3 2019 | $9,548,000 | – | 118,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |